Floatz logo

Nirogacestat

Metastatic Cancer Pancreas

PfizerSmall moleculePhase 2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

190 Active assets in the Metastatic Cancer Pancreas cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Jonsson Comprehensive Cancer Center
Phase 4BBB
Docetaxel
Bristol-Myers Squibb
Phase 2BBB
Irinotecan
Jonsson Comprehensive Cancer Center
Phase 3BB
Eloxatin
Jonsson Comprehensive Cancer Center
Phase 4BB
Irinotecan
Ipsen
Phase 3BB

View all 50 →

Same molecule, other indications

Nirogacestat is also rated in:

neoplasmDormant
CCC
Indicative ·
50 / 100
View asset →
ovarian granulosa cell tumorDormant
CCC
Indicative ·
50 / 100
View asset →
ovarian granulosa cell tumorDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →